<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39373269</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-6992</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>41</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>07</Day></PubDate></JournalIssue><Title>Nano letters</Title><ISOAbbreviation>Nano Lett</ISOAbbreviation></Journal><ArticleTitle>Impact of Lipid Tail Length on the Organ Selectivity of mRNA-Lipid Nanoparticles.</ArticleTitle><Pagination><StartPage>12758</StartPage><EndPage>12767</EndPage><MedlinePgn>12758-67</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.nanolett.4c02566</ELocationID><Abstract><AbstractText>The delivery of mRNA molecules to organs beyond the liver is valuable for therapeutic applications. Functionalized lipid nanoparticles (LNPs) using exogenous mechanisms can regulate <i>in vivo</i> mRNA expression profiles from hepatocytes to extrahepatic tissues but lead to process complexity and cost escalation. Here, we report that mRNA expression gradually shifts from the liver to the spleen in an ionizable lipid tail length-dependent manner. Remarkably, this simple chemical strategy held true even when different ionizable lipid head structures were employed. As a potential mechanism underlying this discovery, our data suggest that 1,2-distearoyl-<i>sn</i>-glycero-3-phosphocholine (DSPC) is enriched on the surface of mRNA/LNPs with short-tail lipids. This feature limits their interaction with biological components, avoiding their rapid hepatic clearance. We also show that spleen-targeting LNPs loaded with SARS-CoV-2 receptor-binding domain (RBD) mRNA can efficiently induce immune responses and neutralize activity following intramuscular vaccination priming and boosting.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hashiba</LastName><ForeName>Kazuki</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-1434-0773</Identifier><AffiliationInfo><Affiliation>Nucleic Acid Medicine Business Division, Nitto Denko Corporation, 1-1-2, Shimohozumi, Ibaraki, Osaka 567-8680, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taguchi</LastName><ForeName>Masamitsu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Nucleic Acid Medicine Business Division, Nitto Denko Corporation, 1-1-2, Shimohozumi, Ibaraki, Osaka 567-8680, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakamoto</LastName><ForeName>Sachiko</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Nucleic Acid Medicine Business Division, Nitto Denko Corporation, 1-1-2, Shimohozumi, Ibaraki, Osaka 567-8680, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otsu</LastName><ForeName>Ayaka</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Nucleic Acid Medicine Business Division, Nitto Denko Corporation, 1-1-2, Shimohozumi, Ibaraki, Osaka 567-8680, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maeda</LastName><ForeName>Yoshiki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Nucleic Acid Medicine Business Division, Nitto Denko Corporation, 1-1-2, Shimohozumi, Ibaraki, Osaka 567-8680, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Yuichi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory for Molecular Design of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-Ku, Sapporo 060-0812, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ebe</LastName><ForeName>Hirofumi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Nucleic Acid Medicine Business Division, Nitto Denko Corporation, 1-1-2, Shimohozumi, Ibaraki, Osaka 567-8680, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okazaki</LastName><ForeName>Arimichi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Nucleic Acid Medicine Business Division, Nitto Denko Corporation, 1-1-2, Shimohozumi, Ibaraki, Osaka 567-8680, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harashima</LastName><ForeName>Hideyoshi</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-1568-9547</Identifier><AffiliationInfo><Affiliation>Laboratory for Molecular Design of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-Ku, Sapporo 060-0812, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-0913-7815</Identifier><AffiliationInfo><Affiliation>Laboratory for Molecular Design of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-Ku, Sapporo 060-0812, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nano Lett</MedlineTA><NlmUniqueID>101088070</NlmUniqueID><ISSNLinking>1530-6984</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">endogenous targeting</Keyword><Keyword MajorTopicYN="N">immune cell</Keyword><Keyword MajorTopicYN="N">ionizable lipids</Keyword><Keyword MajorTopicYN="N">lipid nanoparticles</Keyword><Keyword MajorTopicYN="N">mRNA delivery</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>The authors
declare the following competing financial interest(s): K.H., M.T.,
S.S., A.Ot., Y.M., H.H., and Y.S. are the authors of patents WO2022/071582
(A1) and WO2023191050 (A1) in relation to this publication. K.H.,
M.T., S.S., A.Ot., Y.M., H.E., and A.Ok. were employees of the Nitto
Denko Corporation at the time of this study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>16</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>16</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>7</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39373269</ArticleId><ArticleId IdType="pmc">PMC11487653</ArticleId><ArticleId IdType="doi">10.1021/acs.nanolett.4c02566</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Polack F. P.; et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 2020, 383, 2603–2615. 10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden L. R.; et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 2021, 384, 403–416. 10.1056/NEJMoa2035389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Akinc A.; et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat. Nanotechnol. 2019 2019, 14 (12), 1084–1087. 10.1038/s41565-019-0591-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41565-019-0591-y</ArticleId><ArticleId IdType="pubmed">31802031</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin S.; et al. mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct. Target. Ther. 2022, 71 (7), 1–35. 10.1038/s41392-022-01007-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-01007-w</ArticleId><ArticleId IdType="pmc">PMC9123296</ArticleId><ArticleId IdType="pubmed">35597779</ArticleId></ArticleIdList></Reference><Reference><Citation>Kranz L. M.; et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nat. 2016 2016, 534, 396–401. 10.1038/nature18300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature18300</ArticleId><ArticleId IdType="pubmed">27281205</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas L. A.; et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nat. 2023 2023, 618, 144–150. 10.1038/s41586-023-06063-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06063-y</ArticleId><ArticleId IdType="pmc">PMC10171177</ArticleId><ArticleId IdType="pubmed">37165196</ArticleId></ArticleIdList></Reference><Reference><Citation>Álvarez-Benedicto E.; et al. Spleen SORT LNP Generated in situ CAR T Cells Extend Survival in a Mouse Model of Lymphoreplete B Cell Lymphoma. Angew. Chemie Int. Ed. 2023, 62, e20231039510.1002/anie.202310395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.202310395</ArticleId><ArticleId IdType="pmc">PMC10826899</ArticleId><ArticleId IdType="pubmed">37651468</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo C. J.; et al. Inhaled delivery of a lipid nanoparticle encapsulated messenger RNA encoding a ciliary protein for the treatment of primary ciliary dyskinesia. Pulm. Pharmacol. Ther. 2022, 75, 102134.10.1016/j.pupt.2022.102134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pupt.2022.102134</ArticleId><ArticleId IdType="pubmed">35613658</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei T.; et al. Lung SORT LNPs enable precise homology-directed repair mediated CRISPR/Cas genome correction in cystic fibrosis models. Nat. Commun. 2023 2023, 14, 1–14. 10.1038/s41467-023-42948-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-42948-2</ArticleId><ArticleId IdType="pmc">PMC10640563</ArticleId><ArticleId IdType="pubmed">37951948</ArticleId></ArticleIdList></Reference><Reference><Citation>Akinc A.; et al. Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms. Mol. Ther. 2010, 18, 1357–1364. 10.1038/mt.2010.85.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2010.85</ArticleId><ArticleId IdType="pmc">PMC2911264</ArticleId><ArticleId IdType="pubmed">20461061</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato Y.; Kinami Y.; Hashiba K.; Harashima H. Different kinetics for the hepatic uptake of lipid nanoparticles between the apolipoprotein E/low density lipoprotein receptor and the N-acetyl-d-galactosamine/asialoglycoprotein receptor pathway. J. Controlled Release 2020, 322, 217–226. 10.1016/j.jconrel.2020.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2020.03.006</ArticleId><ArticleId IdType="pubmed">32145269</ArticleId></ArticleIdList></Reference><Reference><Citation>Dilliard S. A.; Cheng Q.; Siegwart D. J. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. Proc. Natl. Acad. Sci. U. S. A. 2021, 118, e210925611810.1073/pnas.2109256118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2109256118</ArticleId><ArticleId IdType="pmc">PMC8719871</ArticleId><ArticleId IdType="pubmed">34933999</ArticleId></ArticleIdList></Reference><Reference><Citation>Rurik J. G.; et al. CAR T cells produced in vivo to treat cardiac injury. Science (80-.) 2022, 375, 91–96. 10.1126/science.abm0594.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm0594</ArticleId><ArticleId IdType="pmc">PMC9983611</ArticleId><ArticleId IdType="pubmed">34990237</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X.; et al. Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis. Nat. Commun. 2023 2023, 14, 1–12. 10.1038/s41467-022-35637-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-35637-z</ArticleId><ArticleId IdType="pmc">PMC9845313</ArticleId><ArticleId IdType="pubmed">36650129</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J. B.; et al. A Glu-urea-Lys Ligand-conjugated Lipid Nanoparticle/siRNA System Inhibits Androgen Receptor Expression In Vivo. Mol. Ther. - Nucleic Acids 2016, 5, e34810.1038/mtna.2016.43.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mtna.2016.43</ArticleId><ArticleId IdType="pmc">PMC5024509</ArticleId><ArticleId IdType="pubmed">28131285</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu M.; et al. Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis. Proc. Natl. Acad. Sci. U. S. A. 2022, 119, e211627111910.1073/pnas.2116271119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2116271119</ArticleId><ArticleId IdType="pmc">PMC8872770</ArticleId><ArticleId IdType="pubmed">35173043</ArticleId></ArticleIdList></Reference><Reference><Citation>Lokugamage M. P.; Sago C. D.; Gan Z.; Krupczak B. R.; Dahlman J. E. Constrained Nanoparticles Deliver siRNA and sgRNA to T Cells In Vivo without Targeting Ligands. Adv. Mater. 2019, 31, 1902251.10.1002/adma.201902251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adma.201902251</ArticleId><ArticleId IdType="pmc">PMC6819129</ArticleId><ArticleId IdType="pubmed">31465135</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni H.; et al. Piperazine-derived lipid nanoparticles deliver mRNA to immune cells in vivo. Nat. Commun. 2022, 10.1038/s41467-022-32281-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32281-5</ArticleId><ArticleId IdType="pmc">PMC9376583</ArticleId><ArticleId IdType="pubmed">35970837</ArticleId></ArticleIdList></Reference><Reference><Citation>Naidu G. S.; et al. A Combinatorial Library of Lipid Nanoparticles for Cell Type-Specific mRNA Delivery. Adv. Sci. 2023, 10, 2301929.10.1002/advs.202301929.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/advs.202301929</ArticleId><ArticleId IdType="pmc">PMC10323619</ArticleId><ArticleId IdType="pubmed">37092557</ArticleId></ArticleIdList></Reference><Reference><Citation>Paunovska K.; et al. The Extent to Which Lipid Nanoparticles Require Apolipoprotein e and Low-Density Lipoprotein Receptor for Delivery Changes with Ionizable Lipid Structure. Nano Lett. 2022, 22, 10025–10033. 10.1021/acs.nanolett.2c03741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.nanolett.2c03741</ArticleId><ArticleId IdType="pubmed">36521071</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X.; et al. An ionizable lipid toolbox for RNA delivery. Nat. Commun. 2021, 12, 7233.10.1038/s41467-021-27493-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27493-0</ArticleId><ArticleId IdType="pmc">PMC8668901</ArticleId><ArticleId IdType="pubmed">34903741</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashiba K.; et al. Overcoming thermostability challenges in mRNA–lipid nanoparticle systems with piperidine-based ionizable lipids. Commun. Biol. 2024 2024, 71 (7), 1–13. 10.1038/s42003-024-06235-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-024-06235-0</ArticleId><ArticleId IdType="pmc">PMC11087515</ArticleId><ArticleId IdType="pubmed">38730092</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashiba K.; et al. Branching ionizable lipids can enhance the stability, fusogenicity, and functional delivery of mRNA. Small Sci. 2023, 3, 2200071.10.1002/smsc.202300285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/smsc.202300285</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Q.; et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat. Nanotechnol. 2020, 15, 313–320. 10.1038/s41565-020-0669-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41565-020-0669-6</ArticleId><ArticleId IdType="pmc">PMC7735425</ArticleId><ArticleId IdType="pubmed">32251383</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu K.; et al. Multiomics analysis of naturally efficacious lipid nanoparticle coronas reveals high-density lipoprotein is necessary for their function. Nat. Commun. 2023, 14, 1–16. 10.1038/s41467-023-39768-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-39768-9</ArticleId><ArticleId IdType="pmc">PMC10325984</ArticleId><ArticleId IdType="pubmed">37414857</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulkarni J. A.; et al. Fusion-dependent formation of lipid nanoparticles containing macromolecular payloads. Nanoscale 2019, 11, 9023–9031. 10.1039/C9NR02004G.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C9NR02004G</ArticleId><ArticleId IdType="pubmed">31021343</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson S. C.; et al. Real time measurement of PEG shedding from lipid nanoparticles in serum via NMR spectroscopy. Mol. Pharmaceutics 2015, 12, 386–392. 10.1021/mp500400k.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/mp500400k</ArticleId><ArticleId IdType="pubmed">25581130</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallud A. Time evolution of PEG-shedding and serum protein coronation determines the cell uptake kinetics and delivery of lipid nanoparticle formulated mRNA. bioRxiv 2021, 10.1101/2021.08.20.457104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.08.20.457104</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulkarni J. A.; et al. On the Formation and Morphology of Lipid Nanoparticles Containing Ionizable Cationic Lipids and siRNA. ACS Nano 2018, 12, 4787–4795. 10.1021/acsnano.8b01516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.8b01516</ArticleId><ArticleId IdType="pubmed">29614232</ArticleId></ArticleIdList></Reference><Reference><Citation>Arteta M. Y.; et al. Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles. Proc. Natl. Acad. Sci. U. S. A. 2018, 115, E3351–E3360. 10.1073/pnas.1720542115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1720542115</ArticleId><ArticleId IdType="pmc">PMC5899464</ArticleId><ArticleId IdType="pubmed">29588418</ArticleId></ArticleIdList></Reference><Reference><Citation>Dehghani-Ghahnaviyeh S.; et al. Ionizable Amino Lipids Distribution and Effects on DSPC/Cholesterol Membranes: Implications for Lipid Nanoparticle Structure. J. Phys. Chem. B 2023, 127, 6928–6939. 10.1021/acs.jpcb.3c01296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jpcb.3c01296</ArticleId><ArticleId IdType="pmc">PMC10424244</ArticleId><ArticleId IdType="pubmed">37498794</ArticleId></ArticleIdList></Reference><Reference><Citation>Parasassi T.; De Stasio G.; Ravagnan G.; Rusch R. M.; Gratton E. Quantitation of lipid phases in phospholipid vesicles by the generalized polarization of Laurdan fluorescence. Biophys. J. 1991, 60, 179–189. 10.1016/S0006-3495(91)82041-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-3495(91)82041-0</ArticleId><ArticleId IdType="pmc">PMC1260049</ArticleId><ArticleId IdType="pubmed">1883937</ArticleId></ArticleIdList></Reference><Reference><Citation>Orlikowska-Rzeznik H.; Krok E.; Chattopadhyay M.; Lester A.; Piatkowski L. Laurdan Discerns Lipid Membrane Hydration and Cholesterol Content. J. Phys. Chem. B 2023, 127, 3382–3391. 10.1021/acs.jpcb.3c00654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jpcb.3c00654</ArticleId><ArticleId IdType="pmc">PMC10123623</ArticleId><ArticleId IdType="pubmed">37021971</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R.; et al. Helper lipid structure influences protein adsorption and delivery of lipid nanoparticles to spleen and liver. Biomater. Sci. 2021, 9, 1449–1463. 10.1039/D0BM01609H.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D0BM01609H</ArticleId><ArticleId IdType="pmc">PMC8753632</ArticleId><ArticleId IdType="pubmed">33404020</ArticleId></ArticleIdList></Reference><Reference><Citation>Pande A. H.; Qin S.; Tatulian S. A. Membrane Fluidity Is a Key Modulator of Membrane Binding, Insertion, and Activity of 5-Lipoxygenase. Biophys. J. 2005, 88, 4084–4094. 10.1529/biophysj.104.056788.</Citation><ArticleIdList><ArticleId IdType="doi">10.1529/biophysj.104.056788</ArticleId><ArticleId IdType="pmc">PMC1305639</ArticleId><ArticleId IdType="pubmed">15778441</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S.; et al. Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR–Cas gene editing. Nat. Mater. 2021 2021, 20, 701–710. 10.1038/s41563-020-00886-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41563-020-00886-0</ArticleId><ArticleId IdType="pmc">PMC8188687</ArticleId><ArticleId IdType="pubmed">33542471</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauffman K. J.; et al. Rapid, Single-Cell Analysis and Discovery of Vectored mRNA Transfection In Vivo with a loxP-Flanked tdTomato Reporter Mouse. Mol. Ther. - Nucleic Acids 2018, 10, 55–63. 10.1016/j.omtn.2017.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2017.11.005</ArticleId><ArticleId IdType="pmc">PMC5734870</ArticleId><ArticleId IdType="pubmed">29499956</ArticleId></ArticleIdList></Reference><Reference><Citation>Galati D.; Zanotta S.; Capitelli L.; Bocchino M. A bird’s eye view on the role of dendritic cells in SARS-CoV-2 infection: Perspectives for immune-based vaccines. Allergy 2022, 77, 100–110. 10.1111/all.15004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.15004</ArticleId><ArticleId IdType="pmc">PMC8441836</ArticleId><ArticleId IdType="pubmed">34245591</ArticleId></ArticleIdList></Reference><Reference><Citation>Teijaro J. R.; Farber D. L. COVID-19 vaccines: modes of immune activation and future challenges. Nat. Rev. Immunol. 2021 2021, 21, 195–197. 10.1038/s41577-021-00526-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00526-x</ArticleId><ArticleId IdType="pmc">PMC7934118</ArticleId><ArticleId IdType="pubmed">33674759</ArticleId></ArticleIdList></Reference><Reference><Citation>Di J.; et al. Biodistribution and Non-linear Gene Expression of mRNA LNPs Affected by Delivery Route and Particle Size. Pharm. Res. 2022, 39, 105–114. 10.1007/s11095-022-03166-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11095-022-03166-5</ArticleId><ArticleId IdType="pmc">PMC8791091</ArticleId><ArticleId IdType="pubmed">35080707</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahl K.; et al. Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses. Mol. Ther. 2017, 25, 1316–1327. 10.1016/j.ymthe.2017.03.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2017.03.035</ArticleId><ArticleId IdType="pmc">PMC5475249</ArticleId><ArticleId IdType="pubmed">28457665</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardi N.; et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J. Controlled Release 2015, 217, 345–351. 10.1016/j.jconrel.2015.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2015.08.007</ArticleId><ArticleId IdType="pmc">PMC4624045</ArticleId><ArticleId IdType="pubmed">26264835</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan C. W.; et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction. Nat. Biotechnol. 2020 2020, 38, 1073–1078. 10.1038/s41587-020-0631-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-020-0631-z</ArticleId><ArticleId IdType="pubmed">32704169</ArticleId></ArticleIdList></Reference><Reference><Citation>Chander N.; Basha G.; Yan Cheng M. H.; Witzigmann D.; Cullis P. R. Lipid nanoparticle mRNA systems containing high levels of sphingomyelin engender higher protein expression in hepatic and extra-hepatic tissues. Mol. Ther. - Methods Clin. Dev. 2023, 30, 235–245. 10.1016/j.omtm.2023.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtm.2023.06.005</ArticleId><ArticleId IdType="pmc">PMC10410000</ArticleId><ArticleId IdType="pubmed">37564393</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z.; et al. Acidification-Induced Structure Evolution of Lipid Nanoparticles Correlates with Their In Vitro Gene Transfections. ACS Nano 2023, 17, 979–990. 10.1021/acsnano.2c06213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.2c06213</ArticleId><ArticleId IdType="pmc">PMC9878718</ArticleId><ArticleId IdType="pubmed">36608273</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R.; et al. Helper lipid structure influences protein adsorption and delivery of lipid nanoparticles to spleen and liver. Biomater. Sci. 2021, 9, 1449–1463. 10.1039/D0BM01609H.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D0BM01609H</ArticleId><ArticleId IdType="pmc">PMC8753632</ArticleId><ArticleId IdType="pubmed">33404020</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebastiani F.; et al. Apolipoprotein E Binding Drives Structural and Compositional Rearrangement of mRNA-Containing Lipid Nanoparticles. ACS Nano 2021, 15, 6709–6722. 10.1021/acsnano.0c10064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.0c10064</ArticleId><ArticleId IdType="pmc">PMC8155318</ArticleId><ArticleId IdType="pubmed">33754708</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamanzi A.; et al. Simultaneous, Single-Particle Measurements of Size and Loading Give Insights into the Structure of Drug-Delivery Nanoparticles. ACS Nano 2021, 15, 19244–19255. 10.1021/acsnano.1c04862.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.1c04862</ArticleId><ArticleId IdType="pubmed">34843205</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng M. H. Y.; et al. Induction of Bleb Structures in Lipid Nanoparticle Formulations of mRNA Leads to Improved Transfection Potency. Adv. Mater. 2023, 35, 2303370.10.1002/adma.202303370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adma.202303370</ArticleId><ArticleId IdType="pubmed">37172950</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C.; Chen C.; Li Y.; Gu R.; Yan X. Characterization of lipid-based nanomedicines at the single-particle level. Fundam. Res. 2023, 3, 488–504. 10.1016/j.fmre.2022.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fmre.2022.09.011</ArticleId><ArticleId IdType="pmc">PMC11197724</ArticleId><ArticleId IdType="pubmed">38933557</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C.; Zhou Y.; Chen C.; Zhu S.; Yan X. Quantification of Available Ligand Density on the Surface of Targeted Liposomal Nanomedicines at the Single-Particle Level. ACS Nano 2022, 16, 6886–6897. 10.1021/acsnano.2c02084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.2c02084</ArticleId><ArticleId IdType="pubmed">35394292</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>